Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis
- 15 August 2007
- journal article
- review article
- Published by Elsevier BV in Journal of the Neurological Sciences
- Vol. 259 (1-2), 27-37
- https://doi.org/10.1016/j.jns.2006.05.071
Abstract
No abstract availableThis publication has 92 references indexed in Scilit:
- Secondary progressive multiple sclerosis: current knowledge and future challengesThe Lancet Neurology, 2006
- The clinical importance of neutralizing antibodies in relapsing-remitting multiple sclerosisCurrent Medical Research and Opinion, 2005
- Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosisThe Lancet Neurology, 2005
- IFN-β1a and IFN-β1b have different patterns of influence on cytokinesClinical Neurology and Neurosurgery, 2004
- Approved and Future Pharmacotherapy for Multiple SclerosisThe Neurologist, 2002
- Use of interferon beta in multiple sclerosis: rationale for early treatment and evidence for dose- and frequency-dependent effects on clinical responseMultiple Sclerosis Journal, 2002
- Combination therapy for treatment of multiple sclerosisAnnals of Neurology, 1998
- MitoxantroneDrugs, 1991
- Pharmacokinetics and Metabolism of MitoxantroneClinical Pharmacokinetics, 1990
- Rating neurologic impairment in multiple sclerosisNeurology, 1983